Chemotherapy-free regimen results in 100% complete response rate, 85% complete molecular remission rate in newly diagnosed patients A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive […]
MD Anderson
MD Anderson and other top U.S. cancer centers call for urgent action to get cancer-preventing HPV vaccination back on track
The COVID-19 pandemic has interrupted delivery of key health services for children and adolescents, including HPV vaccination for cancer prevention The University of Texas MD Anderson Cancer Center has united with fellow National Cancer Institute (NCI)-Designated Cancer Centers and partner organizations to issue […]
MD Anderson and Refuge Biotechnologies collaborate to advance next-generation cell therapies for treatment of solid tumors
Collaboration supports co-development of RB-340 CAR T cell therapy, application of Refuge’s synthetic biology platform to MD Anderson TIL programs The University of Texas MD Anderson Cancer Center and Refuge Biotechnologies, Inc. today announced a strategic collaboration to advance new cell therapies for potential treatment […]
WorkFaith Announces Over 1,000 Jobs At iWork Spring 2021
WorkFaith today announced over 1,000 open job positions at iWork Spring 2021, a virtual two-day hiring event dedicated to Bridging the Skills Gap in America and getting the frontlines back to work. The event, which takes place on April 28 – 29, includes […]
Mutant KRAS and p53 Cooperate To Drive Pancreatic Cancer Metastasis
Preclinical research identifies CREB1 as new therapeutic target downstream of frequently mutated genes Researchers at The University of Texas MD Anderson Cancer Center have discovered that mutant KRAS and p53, the most frequently mutated genes in pancreatic cancer, interact through the CREB1 protein […]
MD Anderson’s Guillermina Lozano Elected to Fellows of the AACR Academy
Guillermina (Gigi) Lozano, Ph.D., chair of Genetics at The University of Texas MD Anderson Cancer Center, has been elected to the 2021 class of Fellows of the American Association for Cancer Research (AACR) Academy in recognition of her pioneering work to describe the […]
Md Anderson’s Therapeutics Discovery Division, Orionis Biosciences Launch Project Helios To Advance Novel Small-Molecule Cancer Medicines
Collaboration designed to uncover new drug-target interactions at genome scale The University of Texas MD Anderson Cancer Center’sTherapeutics Discovery division and Orionis Biosciences today announced the launch of Project Helios, a research collaboration designed to unlock new drug development opportunities through genome-scale mapping of drug-target […]
Focus Fund And Md Anderson Launch Investment Fund To Support Promising Investigational Cancer Therapies In Early-Stage Clinical Trials
Combination of over $50 million in committed capital along with access to cancer expertise and clinical facilities will help advance novel IND-ready candidates The Focus Fund GP, LLC, in partnership with The University of Texas MD Anderson Cancer Center, has launched […]
